ClinVar Miner

Submissions for variant NM_000455.5(STK11):c.559G>A (p.Gly187Ser) (rs587782032)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 9
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000130480 SCV000185349 likely benign Hereditary cancer-predisposing syndrome 2018-10-30 criteria provided, single submitter clinical testing In silico models in agreement (benign);Other data supporting benign classification;Other strong data supporting benign classification
Invitae RCV000198594 SCV000254553 likely benign Peutz-Jeghers syndrome 2020-11-24 criteria provided, single submitter clinical testing
GeneDx RCV000590446 SCV000279178 uncertain significance not provided 2017-08-27 criteria provided, single submitter clinical testing This variant is denoted STK11 c.559G>A at the cDNA level, p.Gly187Ser (G187S) at the protein level, and results in the change of a Glycine to a Serine (GGT>AGT). This variant was observed in at least one individual with triple negative breast cancer (Couch 2015). STK11 Gly187Ser was not observed at a significant allele frequency in large population cohorts (NHLBI Exome Sequencing Project, The 1000 Genomes Consortium 2015, Lek 2016). Since Glycine and Serine differ in polarity, charge, size or other properties, this is considered a non-conservative amino acid substitution. STK11 Gly187Ser occurs at a position that is not conserved and is located in the protein kinase domain and in the region required for binding of substrate and initiation of phospho transfer (UniProt, Hearle 2006). In silico analyses predict that this variant is unlikely to alter protein structure or function. Based on currently available evidence, it is unclear whether STK11 Gly187Ser is a pathogenic or benign variant. We consider it to be a variant of uncertain significance.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000855607 SCV000696722 likely benign not specified 2019-07-10 criteria provided, single submitter clinical testing Variant summary: STK11 c.559G>A (p.Gly187Ser) results in a non-conservative amino acid change located in the catalytic domain (IPR039154) of the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 4.6e-05 in 284338 control chromosomes (gnomAD and publication data). The observed variant frequency is approximately 7 fold of the estimated maximal expected allele frequency for a pathogenic variant in STK11 causing Peutz-Jeghers Syndrome (PJS) phenotype (6.3e-06), strongly suggesting that the variant is benign. Though the variant, c.559G>A, has been reported in the literature in individuals affected with lung-, and breast cancer (Kim_2010, Couch_2015, Momozawa_ 2018), in one of these cases it was noted that the affected patient did not have any clinical manifestations of PJS (Kim_2010); moreover the variant was also reported in multiple healthy controls (Kim_2010, Momozawa_ 2018 and in the FLOSSIES database). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Six other submitters have provided clinical-significance assessments for this variant in ClinVar after 2014, and classified the variant as VUS (4x) or likely benign (2x). Based on the evidence outlined above, the variant was classified as likely benign.
Counsyl RCV000198594 SCV000784804 uncertain significance Peutz-Jeghers syndrome 2017-01-03 criteria provided, single submitter clinical testing
Mendelics RCV000198594 SCV000839415 uncertain significance Peutz-Jeghers syndrome 2018-07-02 criteria provided, single submitter clinical testing
Color Health, Inc RCV000130480 SCV000902824 likely benign Hereditary cancer-predisposing syndrome 2015-09-09 criteria provided, single submitter clinical testing
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000590446 SCV001469918 uncertain significance not provided 2019-12-17 criteria provided, single submitter clinical testing
Department of Pathology and Laboratory Medicine,Sinai Health System RCV001358086 SCV001553735 uncertain significance Malignant tumor of breast no assertion criteria provided clinical testing The STK11 p.Gly187Ser variant was identified in 3 of 10699 proband chromosomes (frequency: 0.0003) from triple negative BRCA families and Japanese women with breast cancer and was present in 2 of 11241 control chromosomes (frequency: 0.00018) from healthy individuals (Couch 2015, Momozawa 20118). The variant was also identified in dbSNP (ID: rs587782032) as “With Uncertain significance allele”, ClinVar (5x as uncertain significance and 1x as likely benign by Ambry Genetics, Invitae, GeneDx, Integrated Genetics, Counsyl, Mendelics) and LOVD 3.0 (4x as uncertain significance). The variant was identified in control databases in 7 of 233812 chromosomes at a frequency of 0.00003 (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: Other in 1 of 5256 chromosomes (freq: 0.0002), European Non-Finnish in 5 of 105720 chromosomes (freq: 0.00005) and East Asian in 1 of 16594 chromosomes (freq: 0.00006), while the variant was not observed in the African, Latino, Ashkenazi Jewish, European Finnish or South Asian populations. The p.Gly187 residue is not conserved in mammals and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) do not suggest a high likelihood of impact to the protein; however, this information is not predictive enough to rule out pathogenicity. The variant occurs outside of the splicing consensus sequence and 2 of 4 in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) predict a greater than 10% difference in splicing; this is not very predictive of pathogenicity. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.